Form 4: Serina Therapeutics CSO Sells Shares After Option Exercise

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, sold 3,102 shares of common stock after exercising options.

Summary

• Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc. (SER), reported transactions on November 4, 2025.
• Exercised 3,102 stock options at an exercise price of $0.06 per share.
• Immediately sold 3,102 shares of common stock at a weighted average price of $4.3953 per share.
• The sales occurred in multiple transactions with prices ranging from $4.35 to $4.65.
• The transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Following these transactions, Moreadith beneficially owns 0 shares of common stock directly and 401,084 stock options.

Sentiment

Score: 4

Explanation: An insider sale, even if pre-planned, can be perceived negatively by the market as it reduces the insider's direct equity stake. However, the transaction was pursuant to a 10b5-1 plan, which mitigates some of the negative sentiment by indicating it was not based on new, non-public information.

Negatives

• Chief Scientific Officer Randall Moreadith sold 3,102 shares of common stock.
• The sale price of $4.3953 is significantly higher than the option exercise price of $0.06, indicating a profit for the insider.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the insider sale as a lack of confidence, though a 10b5-1 plan suggests it's for personal financial planning rather than market timing.

Key Dates

Recommendation

The filing reports an insider sale by the Chief Scientific Officer, Randall Moreadith, following the exercise of stock options. While insider sales can sometimes signal a lack of confidence, this transaction was executed under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not based on new material non-public information. The number of shares sold (3,102) is relatively small compared to the remaining options (401,084), indicating the insider still holds a significant stake. Without additional context on the company's performance or other market factors, a 'hold' recommendation is appropriate, as this single transaction does not provide sufficient information to warrant a 'buy' or 'sell' decision.

Keywords

Serina Therapeutics, SER, Randall Moreadith, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Chief Scientific Officer, 10b5-1 Plan